Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Stocks to Love in 2026

View original at nasdaq.com
Stocks to Love in 2026 In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: Why space is worth watching in 2026.Opportunities in healthcare.How Hims & Hers is disrupting the healthcare industry To catch full episodes of all The Motley Fool's free podcasts, check out our podca…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rocket Lab wants to get Neutron launch right the first time, unlike SpaceX's iterative explosion approach

    80% confidence
  • Expected to move toward profitability in 2026

    80% confidence
  • Healthcare is a market that desperately needs disruption, but it's also between regulation and it is life or death

    80% confidence
  • Raised concerns about TransMedics Medicare reimbursement

    80% confidence
  • Discussed data centers in space with solar power opportunity, more than 5 years away

    80% confidence
  • AI can absorb more real-time patient data than human doctors, such as Garmin watch health data integration

    80% confidence
  • Space investments are high-risk, high-reward

    80% confidence
  • AI has potential to remember/process more medical information than single human physician

    80% confidence
  • Prefers Rocket Lab over SpaceX, even if SpaceX was public

    80% confidence
  • Redwire is owning the fundamental building blocks if we're going to have a Golden Age in space

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
Stocks to Love in 2026 — Source | Via News | Finance Via News